继发于胰腺癌的胰腺外分泌功能不全的研究进展

史晨光; 刘晓欢; 谢亚兴; 马艳波

doi:10.3969/j.issn.1001-5256.2021.04.057

继发于胰腺癌的胰腺外分泌功能不全的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.04.057

1.
山西医科大学第一临床医学院，太原 030001
2.
山西医科大学第一医院普通外科，太原 030001

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：史晨光负责相关文献资料的收集、分析及论文初稿的写作; 刘晓欢、谢亚兴参与文献资料的分析和整理；马艳波负责构思并拟定写作思路，指导论文的写作并最终定稿。

详细信息

作者简介:
史晨光(1995—)，男，主要从事肝胆胰脾外科相关临床研究

通信作者:
马艳波，15103418205@163.com

中图分类号: R735.9
计量
- 文章访问数: 568
- HTML全文浏览量: 241
- PDF下载量: 41
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-11
- 录用日期: 2020-10-13
- 出版日期: 2021-04-20

Research advances in pancreatic exocrine insufficiency secondary to pancreatic cancer

1.
The First Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China
2.
Department of General Surgery, The First Hospital of Shanxi Medical University, Taiyuan 030001, China

摘要

摘要: 目前国际上对胰腺外分泌功能不全的诊断和治疗标准尚未完善，胰腺外科医师对继发于胰腺癌的胰腺外分泌功能不全常常忽视或错误估计，使得胰腺外分泌功能不全未得到充分治疗，严重影响了胰腺癌患者的生存质量。对胰腺癌患者胰腺外分泌功能不全的发病机制、典型症状、诊断方法、不同胰腺癌阶段的胰酶替代治疗等方面的最新研究进展进行了归纳总结, 分析认为胰酶替代治疗能显著改善不同疾病阶段胰腺癌患者的生存质量。
- 胰腺肿瘤 /
- 胰腺外分泌功能不全 /
- 胰酶替代治疗
Abstract: At present, there is still a lack of comprehensive diagnosis and treatment criteria for pancreatic exocrine insufficiency around the world. Pancreatic surgeons often ignore or misjudge pancreatic exocrine insufficiency secondary to pancreatic cancer, and as a result, pancreatic exocrine insufficiency is not adequately treated, which greatly affects the quality of life of patients with pancreatic cancer. This article summarizes the latest research advances in the pathogenesis, typical symptoms, and diagnostic methods of pancreatic exocrine insufficiency, as well as pancreatic enzyme replacement therapy in different stages of pancreatic cancer. It is pointed out that pancreatic enzyme replacement therapy can significantly improve the quality of life of patients with different stages of pancreatic cancer.
- Pancreatic Neoplasms /
- Exocrine Pancreatic Insufficiency /
- Pancreatic Enzyme Replacement Therapy

HTML全文

参考文献(36)

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492
[2]	RAHIB L, SMITH BD, AIZENBERG R, et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74(11): 2913-2921. DOI: 10.1158/0008-5472.CAN-14-0155
[3]	RAWLA P, SUNKARA T, GADUPUTI V. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors[J]. World J Oncol, 2019, 10(1): 10-27. DOI: 10.14740/wjon1166
[4]	PEZZILLI R, CACCIALANZA R, CAPURSO G, et al. Pancreatic enzyme replacement therapy in pancreatic cancer[J]. Cancers, 2020, 12(2): 275. DOI: 10.3390/cancers12020275
[5]	VUJASINOVIC M, VALENTE R, DEL CHIARO M, et al. Pancreatic exocrine insufficiency in pancreatic cancer[J]. Nutrients, 2017, 9(3): 183. DOI: 10.3390/nu9030183
[6]	BARTEL MJ, ASBUN H, STAUFFER J, et al. Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature[J]. Dig Liver Dis, 2015, 47(12): 1013-1020. DOI: 10.1016/j.dld.2015.06.015
[7]	YUASA Y, MURAKAMI Y, NAKAMURA H, et al. Histological loss of pancreatic exocrine cells correlates with pancreatic exocrine function after pancreatic surgery[J]. Pancreas, 2012, 41(6): 928-933. DOI: 10.1097/MPA.0b013e31823d837d
[8]	OKANO K, MURAKAMI Y, NAKAGAWA N, et al. Remnant pancreatic parenchymal volume predicts postoperative pancreatic exocrine insufficiency after pancreatectomy[J]. Surgery, 2016, 159(3): 885-892. DOI: 10.1016/j.surg.2015.08.046
[9]	CAI ZH, LI G, BAO SH, et al. Analysis of influencing factors for pancreatic endocrine and exocrine insufficiency after pancreaticoduodenectomy[J]. Chin J Dig Surg, 2020, 19(4): 414-420. (in Chinese) DOI: 10.3760/cma.j.cn115610-20200409-00243 蔡正华, 李刚, 包善华, 等. 胰十二指肠切除术后发生胰腺内外分泌功能不全的影响因素分析[J]. 中华消化外科杂志, 2020, 19(4): 414-420. DOI: 10.3760/cma.j.cn115610-20200409-00243
[10]	Study Group of Pancreatic Surgery in Chinese Society of Surgery of Chinese Medical Association, Pancreatic Disease Committee of Chinese Research Hospital Association. A consensus statement on the diagnosis and treatment of pancreatic exocrine insufficiency after pancreatic surgery (2018)[J]. Chin J Surg, 2018, 56(9): 641-645. (in Chinese) 中华医学会外科学分会胰腺外科学组, 中国研究型医院学会胰腺疾病专业委员会. 胰腺术后外分泌功能不全诊治的中国专家共识(2018)[J]. 中华外科杂志, 2018, 56(9): 641-645.
[11]	CUI ZK, SU ZL, LU SN, et al. Research progress of pancreatic enzyme replacement therapy after gastric resection[J]. Int J Surg, 2018, 45(4): 276-280. (in Chinese) DOI: 10.3760/cma.j.issn.1673-4203.2018.04.015 崔占昆, 苏志雷, 鲁首男, 等. 胃切除术后胰酶替代治疗的研究进展[J]. 国际外科学杂志, 2018, 45(4): 276-280. DOI: 10.3760/cma.j.issn.1673-4203.2018.04.015
[12]	LI YW, SHEN YN, BAI XL, et al. Research progress of exocrine pancreatic insufficiency after pancreatic operation[J]. Chin J Dig Surg, 2018, 17(12): 1234-1238. (in Chinese) DOI: 10.3760/cma.j.issn.1673-9752.2018.12.017 郦宇炜, 沈艺南, 白雪莉, 等. 胰腺术后胰腺外分泌功能不全的研究进展[J]. 中华消化外科杂志, 2018, 17(12): 1234-1238. DOI: 10.3760/cma.j.issn.1673-9752.2018.12.017
[13]	Special Committee on Chronic Pancreatitis, Pancreatic Disease Specialized Committee, Chinese Medical Doctor Association. Standards for the diagnosis and treatment of pancreatic exocrine insufficiency (2018, Guangzhou)[J]. J Clin Hepatol, 2019, 35(2): 294-298. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.02.010 中国医师协会胰腺病专业委员会慢性胰腺炎专委会. 胰腺外分泌功能不全诊治规范(2018, 广州)[J]. 临床肝胆病杂志, 2019, 35(2): 294-298. DOI: 10.3969/j.issn.1001-5256.2019.02.010
[14]	LINDKVIST B. Diagnosis and treatment of pancreatic exocrine insufficiency[J]. World J Gastroenterol, 2013, 19(42): 7258-7266. DOI: 10.3748/wjg.v19.i42.7258
[15]	GELFOND D. A path to consensus on endoscopic pancreatic function testing[J]. J Pediatr Gastroenterol Nutr, 2019, 68(6): 761-762. http://www.ncbi.nlm.nih.gov/pubmed/30964818
[16]	HORVATH K, MEHTA DI, HILL ID. Assessment of exocrine pancreatic function during endoscopy in children[J]. J Pediatr Gastroenterol Nutr, 2019, 68(6): 768-776. DOI: 10.1097/MPG.0000000000002230
[17]	STEVENS T, PARSI MA. Update on endoscopic pancreatic function testing[J]. World J Gastroenterol, 2011, 17(35): 3957-3961. DOI: 10.3748/wjg.v17.i35.3957
[18]	LIN JH, HU LH, LIAO Z, et al. Clinical application of pancreatic exocrine function examination[J]. Acad J Second Military Med Univ, 2017, 38(10): 1298-1303. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-DEJD201710014.htm 林金欢, 胡良皞, 廖专, 等. 胰腺外分泌功能检测方法应用现状[J]. 第二军医大学学报, 2017, 38(10): 1298-1303. https://www.cnki.com.cn/Article/CJFDTOTAL-DEJD201710014.htm
[19]	DOMÍNGUEZ-MUÑOZ JE, D HARDT P, LERCH MM, et al. Potential for screening for pancreatic exocrine insufficiency using the fecal elastase-1 test[J]. Dig Dis Sci, 2017, 62(5): 1119-1130. DOI: 10.1007/s10620-017-4524-z
[20]	VANGA RR, TANSEL A, SIDIQ S, et al. Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency: Systematic review and Meta-analysiss[J]. Clin Gastroenterol Hepatol, 2018, 16(8): 1220-1228.e4. DOI: 10.1016/j.cgh.2018.01.027
[21]	CAPURSO G, TRAINI M, PICIUCCHI M, et al. Exocrine pancreatic insufficiency: Prevalence, diagnosis, and management[J]. Clin Exp Gastroenterol, 2019, 12: 129-139. DOI: 10.2147/CEG.S168266
[22]	Working Party of the Australasian Pancreatic Club, SMITH RC, SMITH SF, et al. Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency[J]. Pancreatology, 2016, 16(2): 164-180. DOI: 10.1016/j.pan.2015.12.006
[23]	LAYER P, KASHIRSKAYA N, GUBERGRITS N. Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency[J]. World J Gastroenterol, 2019, 25(20): 2430-2441. DOI: 10.3748/wjg.v25.i20.2430
[24]	SPEICHER JE, TRAVERSO LW. Pancreatic exocrine function is preserved after distal pancreatectomy[J]. J Gastrointest Surg, 2010, 14(6): 1006-1011. DOI: 10.1007/s11605-010-1184-0
[25]	ROBERTS KJ, BANNISTER CA, SCHREM H. Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study[J]. Pancreatology, 2019, 19(1): 114-121. DOI: 10.1016/j.pan.2018.10.010
[26]	ROBERTS KJ, SCHREM H, HODSON J, et al. Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy[J]. HPB (Oxford), 2017, 19(10): 859-867. DOI: 10.1016/j.hpb.2017.05.009
[27]	PATHANKI AM, ATTARD JA, BRADLEY E, et al. Pancreatic exocrine insufficiency after pancreaticoduodenectomy: Current evidence and management[J]. World J Gastrointest Pathophysiol, 2020, 11(2): 20-31. DOI: 10.4291/wjgp.v11.i2.20
[28]	PEZZILLI R, ANDRIULLI A, BASSI C, et al. Exocrine pancreatic insufficiency in adults: A shared position statement of the Italian Association for the Study of the Pancreas[J]. World J Gastroenterol, 2013, 19(44): 7930-7946. DOI: 10.3748/wjg.v19.i44.7930
[29]	SIKKENS EC, CAHEN DL, van EIJCK C, et al. The daily practice of pancreatic enzyme replacement therapy after pancreatic surgery: A northern European survey: Enzyme replacement after surgery[J]. J Gastrointest Surg, 2012, 16(8): 1487-1492. DOI: 10.1007/s11605-012-1927-1
[30]	National Health Commission of the People's Republic of China. Diagnosis, management, and treatment of pancreatic adenocarcinoma (V2018)[J]. J Clin Hepatol, 2019, 35(2): 281-293. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.02.009 中华人民共和国国家卫生健康委员会. 胰腺癌诊疗规范(2018年版)[J]. 临床肝胆病杂志, 2019, 35(2): 281-293. DOI: 10.3969/j.issn.1001-5256.2019.02.009
[31]	FATHI A, CHRISTIANS KK, GEORGE B, et al. Neoadjuvant therapy for localized pancreatic cancer: Guiding principles[J]. J Gastrointest Oncol, 2015, 6(4): 418-429. http://pubmedcentralcanada.ca/pmcc/articles/PMC4502155/
[32]	CHABOT JA, TSAI WY, FINE RL, et al. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer[J]. J Clin Oncol, 2010, 28(12): 2058-2063. DOI: 10.1200/JCO.2009.22.8429
[33]	SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI: 10.3322/caac.21551
[34]	LANDERS A, BROWN H, STROTHER M. The effectiveness of pancreatic enzyme replacement therapy for malabsorption in advanced pancreatic cancer, a pilot study[J]. Palliat Care, 2019, 12: 1178224218825270. http://www.ncbi.nlm.nih.gov/pubmed/30799929
[35]	DOMÍNGUEZ-MUÑOZ JE, NIETO-GARCIA L, LÓPEZ-DÍAZ J, et al. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: A retrospective analysis[J]. BMC Cancer, 2018, 18(1): 534. DOI: 10.1186/s12885-018-4439-x
[36]	WOO SM, JOO J, KIM SY, et al. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial[J]. Pancreatology, 2016, 16(6): 1099-1105. DOI: 10.1016/j.pan.2016.09.001